Inhibikase Reports Third Quarter 2025 Financial Results
Inhibikase Therapeutics reported third-quarter 2025 results and set a near-term catalyst: the initiation of its Phase 2b IMPROVE-PAH study...
Tevogen Highlights Successful Capital Efficiency in Q3 Filing
Tevogen Bio filed its Q3 2025 10-Q, reporting a GAAP operating loss of $5.7 million for the quarter, a...
Prelude Therapeutics Q3 2025 Financials & Corporate Update
Prelude Therapeutics outlined a 2026 clinical re-entry, built around two precision oncology assets: advancing a mutant-selective JAK2V617F JH2 allosteric...
Zenas Biopharma Q3 2025 Results & A Timely Corporate Update
Zenas Biopharma (Nasdaq: ZBIO) packed several catalysts into its latest update: topline data from the phase 3 Indigo trial...
Cosciens Biopharma Q3 Results & New Strategic Focus Update
Cosciens Biopharma has voluntarily delisted from Nasdaq, maintained its Toronto Stock Exchange listing, and is seeking quotation on the...
Opus Genetics Q3 2025 Financial Results, Corporate Update
Opus Genetics reported a pivotal quarter for its inherited retinal disease portfolio, highlighting positive Phase 1/2 data for its...
Legend Biotech Reports Third Quarter 2025 Financial Results
Legend Biotech reported third-quarter 2025 results anchored by accelerating commercial momentum for Carvykti, including estimated net trade sales of...
TScan Delivers Q3 2025 Financial Results, Corporate Update
TScan Therapeutics has secured FDA alignment on a pivotal trial design for TSC-101 in post-transplant hematologic malignancies, implemented a...
Announcing Humacyte’s Q3 2025 Results & Business Update
Humacyte reported third-quarter 2025 revenue of $753,000, primarily driven by a ramp in U.S. sales of SymVESS, its FDA-approved...
Metagenomi Announces Q3 Results, New Strategic Focus & Updates
Metagenomi has restructured around a single, near-term bet: in vivo genome editing for hemophilia A. The company reported new...